Neoadjuvant combination immunotherapy in MSI/dMMR colorectal cancer

被引：0

作者：

Suarez-Carmona, Meggy ^{[1
,2
]}

Halama, Niels ^{[1
,2
,3
,4
]}

机构：

[1] German Canc Res Ctr, Dept Canc Immunol & Canc Immunotherapy, Heidelberg, Germany

[2] Helmholtz Inst Translat Oncol HI TRON, Mainz, Germany

[3] Johannes Gutenberg Univ Mainz, Univ Canc Ctr Mainz UCT Mainz, Univ Med Ctr, Mainz, Germany

[4] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Hematol Med Oncol & Pneumol, Mainz, Germany

来源：

TRENDS IN CANCER | 2024年 / 10卷 / 12期

关键词：

MISMATCH REPAIR-DEFICIENT; NIVOLUMAB;

D O I：

10.1016/j.trecan.2024.10.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Neoadjuvant immune checkpoint inhibition (ICI) is a new approach to treat patients with colorectal cancer (CRC). The effects of combined neoadjuvant ICI in locally advanced, DNA mismatch repair (dMMR)-deficient/microsatellite instable (MSI) CRC were recently reported by de Gooyer et al. from the NICHE-3 trial. Further studies will determine whether these impressive pathological responses lead to long-term clinical benefit.

引用

页码：1093 / 1094

页数：2

共 50 条

[31] Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer
Inamori, Koji
Togashi, Yosuke
Fukuoka, Shota
Akagi, Kiwamu
Ogasawara, Kouetsu
Irie, Takuma
Motooka, Daisuke
Kobayashi, Yoichi
Sugiyama, Daisuke
Kojima, Motohiro
Shiiya, Norihiko
Nakamura, Shota
Maruyama, Shoichi
Suzuki, Yutaka
Ito, Masaaki
Nishikawa, Hiroyoshi
JCI INSIGHT, 2021, 6 (09)
[32] Pembrolizumab in MSI-H-dMMR Advanced Colorectal Cancer - A New Standard of Care
Grothey, Axel
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (23): : 2283 - 2285
[33] PD-1 inhibition in metastatic dMMR/MSI-H colorectal cancer
Sclafani, Francesco
LANCET ONCOLOGY, 2017, 18 (09): : 1141 - 1142
[34] Neoadjuvant pembrolizumab for localized solid MSI-H/dMMR tumors
Kessing, Richard
ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2023, 61 (10):
[35] Correlation between metastatic site and immunotherapy efficacy in patients with advanced dMMR/MSI colorectal cancer: Real-World Italian multicentric retrospective study (Colon-MSI)
Iachetta, Francesco
Cremolini, Chiara
Ciardiello, Giamaica
Damato, Angela
Bernardini, Ilaria
Iacono, Donatella
Di Fabio, Francesca
Palazzo, Michele
Caputo, Francesco
Gelsomino, Fabio
Banzi, Maria
Brugia, Marco
Frassineti, Luca
Grizzi, Giulia
Germani, Marco Maria
Santucci, Sara
Russo, Alessia Erika
Garajova, Ingrid
Frisinghelli, Michela
Pinto, Carmine
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[36] KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer
Andre, Thierry
Pietrantonio, Filippo
Avallone, Antonio
Gumus, Mahmut
Wyrwicz, Lucjan
Kim, Jong Gwang
Yalcin, Suayib
Kwiatkowski, Mariusz
Lonardi, Sara
Zolnierek, Jakub
Odeleye-Ajakaye, Amos
Leconte, Pierre
Fogelman, David
Kim, Tae Won
FUTURE ONCOLOGY, 2023, 19 (37) : 2445 - 2452
[37] Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer
Trojan, Jorg
Stintzing, Sebastian
Haase, Oliver
Koch, Christine
Ziegler, Paul
Demes, Melanie
Jelas, Ivan
ONCOLOGIST, 2021, 26 (12): : E2110 - E2114
[38] Prevalence of NTRK1/2/3 fusions in dMMR/MSI metastatic colorectal cancer
Svrcek, M.
Colle, R.
Cayre, A.
Mas, L.
Bourgoin, P.
Cohen, R.
Andre, T.
Penault-Llorca, F.
Radosevic-Robin, N.
ANNALS OF ONCOLOGY, 2021, 32 : S556 - S556
[39] Neoadjuvant immunotherapy in primary and metastatic colorectal cancer
Kanani, A.
Veen, T.
Soreide, K.
BRITISH JOURNAL OF SURGERY, 2021, 108 (12) : 1417 - 1425
[40] Neoadjuvant envafolimab in a patient with MSI-H/dMMR colon cancer: a case report and literature review
Chen, Ziwei
Zhou, Jingrui
Chen, Weimin
Wu, Tao
Lian, Ke
Shen, Tao
IMMUNOTHERAPY, 2024, 16 (10) : 649 - 657

← 1 2 3 4 5 →